Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
CRAD B Stock Overview
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide.
Rewards
Risk Analysis
CRAD B passed our risk checks.
C-Rad Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr41.15 |
52 Week High | kr67.40 |
52 Week Low | kr35.00 |
Beta | 1.16 |
1 Month Change | 0% |
3 Month Change | -15.59% |
1 Year Change | -18.68% |
3 Year Change | 12.43% |
5 Year Change | 82.08% |
Change since IPO | 174.33% |
Recent News & Updates
Returns Are Gaining Momentum At C-Rad (STO:CRAD B)
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...
Shareholder Returns
CRAD B | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | -4.2% | 5.6% | -1.3% |
1Y | -18.7% | -35.0% | -23.6% |
Return vs Industry: CRAD B exceeded the Swedish Medical Equipment industry which returned -35% over the past year.
Return vs Market: CRAD B exceeded the Swedish Market which returned -23.6% over the past year.
Price Volatility
CRAD B volatility | |
---|---|
CRAD B Average Weekly Movement | 6.9% |
Medical Equipment Industry Average Movement | 8.4% |
Market Average Movement | 7.4% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 4.7% |
Stable Share Price: CRAD B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CRAD B's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 70 | Tim Thurn | https://www.c-rad.se |
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery.
C-Rad Fundamentals Summary
CRAD B fundamental statistics | |
---|---|
Market Cap | kr1.39b |
Earnings (TTM) | kr20.70m |
Revenue (TTM) | kr257.45m |
67.1x
P/E Ratio5.4x
P/S RatioIs CRAD B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRAD B income statement (TTM) | |
---|---|
Revenue | kr257.45m |
Cost of Revenue | kr87.02m |
Gross Profit | kr170.43m |
Other Expenses | kr149.73m |
Earnings | kr20.70m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 21, 2022
Earnings per share (EPS) | 0.61 |
Gross Margin | 66.20% |
Net Profit Margin | 8.04% |
Debt/Equity Ratio | 0% |
How did CRAD B perform over the long term?
See historical performance and comparisonValuation
Is CRAD B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRAD B?
Other financial metrics that can be useful for relative valuation.
What is CRAD B's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | kr1.39b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 5x |
Enterprise Value/EBITDA | 40x |
PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does CRAD B's PE Ratio compare to its peers?
CRAD B PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 856.8x |
Price-To-Earnings vs Peers: CRAD B is good value based on its Price-To-Earnings Ratio (67.1x) compared to the peer average (856.8x).
Price to Earnings Ratio vs Industry
How does CRAD B's PE Ratio compare vs other companies in the Medical Equipment Industry?
Price-To-Earnings vs Industry: CRAD B is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the Swedish Medical Equipment industry average (35.8x)
Price to Earnings Ratio vs Fair Ratio
What is CRAD B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 67.1x |
Fair PE Ratio | 50.7x |
Price-To-Earnings vs Fair Ratio: CRAD B is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the estimated Fair Price-To-Earnings Ratio (50.7x).
Share Price vs Fair Value
What is the Fair Price of CRAD B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CRAD B (SEK41.15) is trading below our estimate of fair value (SEK99.15)
Significantly Below Fair Value: CRAD B is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: CRAD B is poor value based on its PEG Ratio (1.6x)
Discover undervalued companies
Future Growth
How is C-Rad forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
5/6Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
41.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRAD B's forecast earnings growth (41.9% per year) is above the savings rate (0.3%).
Earnings vs Market: CRAD B's earnings (41.9% per year) are forecast to grow faster than the Swedish market (9.8% per year).
High Growth Earnings: CRAD B's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CRAD B's revenue (15.4% per year) is forecast to grow faster than the Swedish market (5.6% per year).
High Growth Revenue: CRAD B's revenue (15.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRAD B's Return on Equity is forecast to be high in 3 years time (22.3%)
Discover growth companies
Past Performance
How has C-Rad performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
44.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRAD B has high quality earnings.
Growing Profit Margin: CRAD B's current net profit margins (8%) are higher than last year (7.5%).
Past Earnings Growth Analysis
Earnings Trend: CRAD B has become profitable over the past 5 years, growing earnings by 44% per year.
Accelerating Growth: CRAD B's earnings growth over the past year (20.6%) is below its 5-year average (44% per year).
Earnings vs Industry: CRAD B earnings growth over the past year (20.6%) exceeded the Medical Equipment industry 6.3%.
Return on Equity
High ROE: CRAD B's Return on Equity (9%) is considered low.
Discover strong past performing companies
Financial Health
How is C-Rad's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: CRAD B's short term assets (SEK260.5M) exceed its short term liabilities (SEK64.9M).
Long Term Liabilities: CRAD B's short term assets (SEK260.5M) exceed its long term liabilities (SEK6.0M).
Debt to Equity History and Analysis
Debt Level: CRAD B is debt free.
Reducing Debt: CRAD B has no debt compared to 5 years ago when its debt to equity ratio was 19.2%.
Debt Coverage: CRAD B has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRAD B has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is C-Rad current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRAD B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRAD B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRAD B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRAD B's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRAD B has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Tim Thurn (40 yo)
8.92yrs
Tenure
kr2,196,000
Compensation
Mr. Tim Thurn has been the Chief Executive Officer of C-Rad AB since July 1, 2013 and serves as its President since July 1, 2013. Mr. Thurn has been the Chief Executive Officer of C-Rad Imaging AB since 20...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD216.86K) is about average for companies of similar size in the Swedish market ($USD228.60K).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: CRAD B's management team is considered experienced (2.5 years average tenure).
Board Members
Experienced Board: CRAD B's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CRAD B insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
C-Rad AB (publ)'s employee growth, exchange listings and data sources
Key Information
- Name: C-Rad AB (publ)
- Ticker: CRAD B
- Exchange: OM
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: kr1.390b
- Shares outstanding: 33.77m
- Website: https://www.c-rad.se
Number of Employees
Location
- C-Rad AB (publ)
- SjukhusvAegen 12K
- Uppsala
- Uppsala County
- 753 09
- Sweden
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/24 00:00 |
End of Day Share Price | 2022/06/23 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.